2. Search Result
Search Result
Results for "

retinal edema

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

4

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14648A
    Dexamethasone acetate
    5+ Cited Publications

    Dexamethasone 21-acetate; Hexadecadrol acetate

    		 Glucocorticoid Receptor Inflammation/Immunology
    Dexamethasone acetate (Dexamethasone 21-acetate) is the acetate form of the glucocorticoid Dexamethasone (HY-14648). Dexamethasone acetate has a longer duration of action than Dexamethasone. Dexamethasone acetate can accumulate at inflammatory sites, in mouse liver and mouse lung via nanostructured lipid carriers. Dexamethasone acetate can be used to prepare topical formulations for studies related to sensorineural hearing loss, γ-carrageenan-induced paw edema, chronic active hepatitis, pulmonary diseases, and inflammation after vitreoretinal surgery .
    Dexamethasone acetate
  • HY-P99116
    Faricimab

    RG7716; RO-6867461

    		 VEGFR Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
    Faricimab
  • HY-145633
    Sozinibercept

    OPT 302; VGX-300

    		 VEGFR Cardiovascular Disease
    Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .
    Sozinibercept
  • HY-P990012
    Vamikibart

    EBI-031

    		 Interleukin Related Inflammation/Immunology
    Vamikibart (RG6179) is a monoclonal antibody targeting IL-6 that can be used to inhibit uveal macular edema (UME) and reduce retinal leakage. Vamikibart can reduce anterior chamber (AC) cell density, indicating a reduction in intraocular inflammation. Vamikibart can also be used to assess the leakage dynamics of ultra-wide-angle fluorescein angiography (UWFA) in the UME model to quantify changes in retinal leakage reflecting the effect of UME inhibition .
    Vamikibart
  • HY-136642
    Fluocinolone

    		Glucocorticoid Receptor Inflammation/Immunology
    Fluocinolone is a potent steroid with highly selective glucocorticoid receptor agonist activity. Fluocinolone stabilizes the blood-retinal barrier by enhancing endothelial tight junctions, inhibiting the VEGF pathway and inflammatory factors. Fluocinolone has high lipophilicity, enabling long-term sustained release in the vitreous. Fluocinolone is used in research related to dermatological diseases, diabetic macular edema, uveitis and oral lichen planus .
    Fluocinolone
  • HY-P991293
    NN-2101

    		c-Kit Metabolic Disease
    NN-2101 is a human monoclonal antibody (mAb) targeting c-Kit/CD117. NN-2101 is used in the research of retinal disorders and diabetic macular edema.
    NN-2101
  • HY-178919
    N-19004

    		Formyl Peptide Receptor (FPR) Apoptosis Bacterial Inflammation/Immunology
    N-19004 is a FPR1 antagonist. N-19004 shows broad-spectrum antibacterial effects against a variety of pathogens. N-19004 exhibits significant retinal protective effects in the rd10 mouse model of retinitis pigmentosa (RP). N-19004 can attenuate retinal dysfunction, mitigate rod and cone degeneration, and reduce immune cell activation, gliosis, inflammation, oxidative stress, and apoptosis. N-19004 can reduce the size of laser-induced choroidal lesions and promote edema absorption through dual anti-inflammatory and anti-angiogenic effects. N-19004 can be used for the research of retinal degenerative diseases such as retinitis pigmentosa .
    N-19004
  • HY-W423707
    TG 100948

    		VEGFR Cardiovascular Disease
    TG 100948 is a dual VEGFR and tyrosine kinase Src inhibitor. TG 100948 reduces retinal edema and retinal thickening, and eliminates bullous edema cysts in a rat model of ischemic retinal vein occlusion. TG 100948 can be used for the research of ischemic retinal vein occlusion .
    TG 100948
  • HY-136642R
    Fluocinolone (Standard)

    		Reference Standards Glucocorticoid Receptor Inflammation/Immunology
    Fluocinolone (Standard) is the analytical standard of Fluocinolone (HY-136642). This product is intended for research and analytical applications. Fluocinolone is a potent steroid with highly selective glucocorticoid receptor agonist activity. Fluocinolone stabilizes the blood-retinal barrier by enhancing endothelial tight junctions, inhibiting the VEGF pathway and inflammatory factors. Fluocinolone has high lipophilicity, enabling long-term sustained release in the vitreous. Fluocinolone is used in research related to dermatological diseases, diabetic macular edema, uveitis and oral lichen planus .
    Fluocinolone (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: